Meza PA, Rodarte ER, Vázquez CJL

Language: Spanish
References: 15
Page: 6-10
PDF size: 186.01 Kb.

ABSTRACT

In spite of the noticeable decrease of the disease caused by Bordetella pertussis since the introduction of the vaccination against it in 1940, pertussis disease keeps on being an endemic disease all over the world and represents an important cause of morbidity and death in both developing and developed countries.
In this retrospective review, it could be confirmed that pertussis remains as a health problem at our hospital, with an average of 9.3 cases a year and a prevalence of 0.72% in the three follow-up years. The age of presentation of the disease was inversely proportional to the risk magnitude; this means to say that the younger the child is, the higher is the risk of dying.
The increase of leucocytes due to lymphocytosis was associated to a greater diagnostic probability of pertussis disease.
The nutritional status or the feeding habit history when breast-feeding was not a determinant factor in the presentation of the disease.
Mortality was observed in three (10%) patients and it was related to complications such as septicemia or cardiac-respiratory insufficiency.
It can be concluded that a complete vaccination schedule is a decisive factor in order to obtain optimal immunity. Pertussis disease should not be considered a benign disease, since its complications may bring people close to death.

REFERENCES

1. Pichichero M, Blatter M, Kenedy W. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 2006; 117: 1084-1093.

2. Cortesse MM, Baugman Al, Brown K, Srivastata P. A “new age” in pertussis prevention new opportunities through adult vaccination. Am J Prev Med 2007; 32(3): 177-185.

3. Tosí AE, Rava L, Ciofi ML, Salmaso S. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six year of life. Pediatrics 2003; 112: 1069-1075.

4. Heinninger U, Kleemann WJ, Cherry JD. A controller study of relationship between Bordetella pertussis infections and sudden unexpected deahts among german infants. Pediatrics 2004; 114: 9-15.

5. Kowalzik F, Prata B et al. Prospective multinational study of pertussis infection in hospitalized infants and their household contacts. Pediatr Infect Dis J 2007; 26: 238-241.

6. Black S. Epidemiology of pertussis. Pediatric Infect Dis J 1997; 16(suppl 4): 85-89.

7. Ward J, Cherry J, Chang S, Partridge S. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353: 1555-1563.

8. Lee G, LeBaron Ch, Murphy T, Lett S. Pertussis in adolescents and adult: Should We Vaccinate? Pediatrics 2005; 115: 1675-1684.

9. Braman S. Postinfectious Cough: ACCP evidence-based clinical practice guidelines. Chest 2005; 129: 138S-146S.

10. Acellular pertussis vaccines efficacious in adolescents and adults. J Watch Infect Dis 2005: 2-2.

11. Cherry J. The epidemiology of pertussis: A Comparison of the epidemiology of disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005;115: 1422-1427.

12. Gonik B, Puder K, Gonik N, Kruger M. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. Infect Dis Obstet Gynecol 2005; 13: 59-61.

13. Wortis N, Strebel P, Wharton M, Bardenheier B, Hardy I. Pertussis Death: Report of 23 cases in the United States, 1992 and 1993. Pediatrics 1996; 97: 607-612.

14. Bisgard K, Rhodes P, Connelly B, Hahn C, Patrick S, Glodé M, Ehresmann K. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 2005; 116: 285-294.

15. Brooks DA, Clover R. Pertussis Infection in the United States: role for vaccination of adolescents and adults. J Am Board Fam Med 2006; 19: 603-11.